Aimmune Therapeutics, Inc. (AIMT) CEO Stephen George Dilly Sells 1,154 Shares

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) CEO Stephen George Dilly sold 1,154 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $26.24, for a total transaction of $30,280.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stephen George Dilly also recently made the following trade(s):

  • On Friday, October 6th, Stephen George Dilly sold 4,047 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.31, for a total transaction of $106,476.57.
  • On Thursday, October 5th, Stephen George Dilly sold 14,689 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.24, for a total transaction of $385,439.36.
  • On Wednesday, October 4th, Stephen George Dilly sold 80,110 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $26.23, for a total transaction of $2,101,285.30.
  • On Monday, September 25th, Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $25.01, for a total transaction of $2,501,000.00.
  • On Wednesday, July 26th, Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $21.46, for a total transaction of $1,073,000.00.

Shares of Aimmune Therapeutics, Inc. (NASDAQ AIMT) traded up 1.80% during midday trading on Wednesday, hitting $26.02. 237,999 shares of the stock were exchanged. The company’s market capitalization is $1.31 billion. Aimmune Therapeutics, Inc. has a 1-year low of $14.87 and a 1-year high of $27.31. The firm has a 50-day moving average of $24.54 and a 200-day moving average of $24.54.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). On average, equities analysts expect that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.com-unik.info/2017/10/18/aimmune-therapeutics-inc-aimt-ceo-stephen-george-dilly-sells-1154-shares.html.

Institutional investors have recently added to or reduced their stakes in the company. Palo Alto Investors LLC grew its holdings in shares of Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after purchasing an additional 793,771 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Aimmune Therapeutics by 30.5% in the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after purchasing an additional 513,803 shares in the last quarter. State Street Corp grew its holdings in shares of Aimmune Therapeutics by 49.1% in the first quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after purchasing an additional 282,744 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Aimmune Therapeutics by 67.3% in the first quarter. Point72 Asset Management L.P. now owns 681,973 shares of the biotechnology company’s stock valued at $14,819,000 after purchasing an additional 274,273 shares in the last quarter. Finally, Eagle Asset Management Inc. grew its holdings in shares of Aimmune Therapeutics by 6.3% in the second quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock valued at $46,674,000 after purchasing an additional 135,374 shares in the last quarter. Hedge funds and other institutional investors own 72.90% of the company’s stock.

A number of equities analysts have commented on AIMT shares. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, July 24th. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. Aimmune Therapeutics presently has an average rating of “Hold” and a consensus price target of $40.00.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

What are top analysts saying about Aimmune Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aimmune Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit